Globus Medical (GMED) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Globus Medical (NYSE: GMED):

• 1/9/2026 – Globus Medical had its price target raised by analysts at Canaccord Genuity Group Inc. from $105.00 to $112.00. They now have a “buy” rating on the stock.
• 1/8/2026 – Globus Medical had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $115.00 price target on the stock, up previously from $90.00.
• 1/8/2026 – Globus Medical had its “market perform” rating reaffirmed by analysts at Citigroup Inc..
• 1/3/2026 – Globus Medical was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 12/30/2025 – Globus Medical had its “neutral” rating reaffirmed by analysts at BTIG Research.
• 12/17/2025 – Globus Medical had its price target raised by analysts at Royal Bank Of Canada from $92.00 to $100.00. They now have an “outperform” rating on the stock.
• 12/17/2025 – Globus Medical had its price target raised by analysts at Canaccord Genuity Group Inc. from $90.00 to $105.00. They now have a “buy” rating on the stock.
• 12/9/2025 – Globus Medical was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 12/6/2025 – Globus Medical was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 12/2/2025 – Globus Medical had its price target raised by analysts at Morgan Stanley from $70.00 to $100.00. They now have an “overweight” rating on the stock.

Insider Transactions at Globus Medical

In other Globus Medical news, CFO Kyle Kline sold 3,594 shares of the firm’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total value of $363,353.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Stephen T. Zarrilli sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $84.29, for a total transaction of $2,107,250.00. The disclosure for this sale is available in the SEC filing. Insiders sold 91,636 shares of company stock valued at $7,984,583 over the last three months. 18.51% of the stock is currently owned by company insiders.

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.